Sesen Bio, Inc. (SESN) News

Sesen Bio, Inc. (SESN): $0.55

0.02 (+3.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add SESN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 382

in industry

Filter SESN News Items

SESN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

SESN News Highlights

  • For SESN, its 30 day story count is now at 2.
  • Over the past 4 days, the trend for SESN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
  • BIO are the most mentioned tickers in articles about SESN.

Latest SESN News From Around the Web

Below are the latest news stories about SESEN BIO INC that investors may wish to consider to help them evaluate SESN as an investment opportunity.

Sesen Bio Reports Third Quarter 2022 Financial Results and Business Update

CAMBRIDGE, Mass., November 07, 2022--Sesen Bio (Nasdaq: SESN) today reported operating results for the third quarter ended September 30, 2022, and provided a business update.

Yahoo | November 7, 2022

SESEN BIO, INC. (SESN) Gains As Market Dips: What You Should Know

SESEN BIO, INC. (SESN) closed the most recent trading day at $0.56, moving +1.8% from the previous trading session.

Yahoo | November 3, 2022

Sesen Bio (SESN) to Report Q3 Earnings: What's in the Cards?

Sesen Bio's (SESN) third-quarter earnings are likely to reflect the cost savings from the company's restructuring plans.

Yahoo | October 27, 2022

SESEN BIO, INC. (SESN) Flat As Market Gains: What You Should Know

In the latest trading session, SESEN BIO, INC. (SESN) closed at $0.50, marking no change from the previous day.

Yahoo | October 21, 2022

SESEN BIO, INC. (SESN) Dips More Than Broader Markets: What You Should Know

SESEN BIO, INC. (SESN) closed at $0.50 in the latest trading session, marking a -1.81% move from the prior day.

Yahoo | October 12, 2022

SESEN BIO, INC. (SESN) Stock Moves -0.43%: What You Should Know

SESEN BIO, INC. (SESN) closed at $0.39 in the latest trading session, marking a -0.43% move from the prior day.

Yahoo | September 29, 2022

Wave Therapeutics (WVE) Up on Update From Huntington's Study

Wave Therapeutics (WVE) provides a positive update from its ongoing phase Ib/IIa study evaluating one of its lead candidates, WVE-003, for Huntington's disease. Stock up.

Yahoo | September 21, 2022

Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

Yahoo | September 21, 2022

Novartis, Moderna Partner Agrees To Merge With Beleaguered Sesen Bio

Sesen Bio Inc (NASDAQ: SESN) and privately held Carisma Therapeutics Inc have entered into a merger agreement to combine the companies in an all-stock transaction. The combined company will operate under the Carisma Therapeutics moniker under the "CARM symbol" and is expected to have approximately $180 million of cash and cash equivalents, including $30 million from concurrent financing by Carisma, which is expected to fund the company through 2024. Sesen Bio suffered FDA rejection for its lead

Yahoo | September 21, 2022

Sesen Bio and Carisma Therapeutics Announce Merger Agreement

CAMBRIDGE, Mass. & PHILADELPHIA, September 21, 2022--Sesen Bio, Inc. (Nasdaq: SESN) and Carisma Therapeutics Inc. (Carisma), a privately held, clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on the advancement of Carisma’s proprietary cell therapy platform that utilizes engineered

Yahoo | September 21, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5614 seconds.